Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

23.39 +0.11 (+0.45%)
Streaming Delayed Price Updated: 11:41 AM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023
The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) is a Stock Spotlight on 4/11
Via Investor Brand Network
News headline image
1 Growth Stock to Buy Before the Next Bull Market ↗
The stock is on a roll, and the company just made a major new purchase. 
Via The Motley Fool
News headline image
Analyst Expectations for Catalyst Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
7 A-Rated Stocks to Buy for April 2023 ↗
Now that the first quarter's in the bank, here are seven A-rated stocks to buy for April to keep your portfolio in top-notch shape. 
Via InvestorPlace
News headline image
2 Top Growth Stocks That Can Withstand an Economic Downturn ↗
These two drugmakers should march higher in 2023 and beyond. 
Via The Motley Fool
News headline image
4 Analysts Have This to Say About Catalyst Pharmaceuticals ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Earnings Outlook For Catalyst Pharmaceuticals ↗
 
Via Benzinga
Here's How Much $1000 Invested In Catalyst Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Why Catalyst Pharmaceuticals Shares Are Moving ↗
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading higher by 9.66% to $15.72 Thursday morning after the company reported better-than-expected fourth-quarter results. 
Via Benzinga
News headline image
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates ↗
The guidance includes Catalyst's newest, and second, product. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
7 Core Stocks to Build a Solid Portfolio Around ↗
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation. 
Via InvestorPlace
News headline image
Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 15, 2023 ↗
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
News headline image
2 Growth Stocks to Invest $1,000 in Right Now ↗
Both of these biopharmas have major catalysts that are in play or drawing near. 
Via The Motley Fool
News headline image
2 Breakout Growth Stocks to Buy for the Long Haul ↗
These two stocks are entirely different, but they both make shareholders richer. 
Via The Motley Fool
News headline image
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023
The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
7 Smart Stock Picks for Cautious Investors ↗
As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors. 
Via InvestorPlace
News headline image
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharma Reveals Interim Q4 Earnings, Says Well Positioned For 2023 ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The 7 Best Growth Stocks to Buy for February 2023 ↗
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors. 
Via InvestorPlace
News headline image
Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review ↗
Stocks reacted well to uneven earnings and economic reports. 
Via Investor's Business Daily
News headline image
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed? ↗
Things aren't as bad as they might seem. 
Via The Motley Fool
News headline image
How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback ↗
Catalyst is adding to its portfolio with a $160 million deal. 
Via Investor's Business Daily
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.